Xoma (US) LLC
15 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 2 name spellings.
10
Ending by 2030
Mar 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Nov 21, 2026The maintenance fee for Flexible Manufacturing System (US 10,294,658) comes due Nov 21, 2026. Unpaid by May 21, 2027, it lapses early.
- 1 fee due Mar 22, 2027The maintenance fee for Methods for the Treatment of Uveitis with IL-1B Binding Antibodies (US 9,139,646) comes due Mar 22, 2027. Unpaid by Sep 22, 2027, it lapses early.
- 2 fees due Apr 17 to 20, 2027 · next Apr 17
- 1 fee due Jun 30, 2027The maintenance fee for Parathyroid Hormone Receptor 1 (PTH1R) Antibodies and Uses Thereof (US 10,519,250) comes due Jun 30, 2027. Unpaid by Jan 3, 2028, it lapses early.
- 1 fee due Aug 11, 2027The maintenance fee for Alpha-Amino Esters of Hydroxypropylthiazolidine Carboxamide Derivative and Salt Form, Crystal Polymorph Thereof (US 10,555,934) comes due Aug 11, 2027. Unpaid by Feb 11, 2028, it lapses early.
- 1 fee due Oct 7, 2027The maintenance fee for Cardiovascular Related Uses of IL-1BETA Antibodies and Binding Fragments Thereof (US 10,611,832) comes due Oct 7, 2027. Unpaid by Apr 7, 2028, it lapses early.
Recent changes
- 1 term has ended since Aug 17, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,531,166 | IL-1BETA Binding Antibodies and Fragments Thereof In force · High confidence | In force | High confidence | |
| US 7,695,718 | Methods for the Treatment of IL-1BETA Related Diseases In force · High confidence | In force | High confidence | |
| US 8,101,166 | Methods for the Treatment of IL-1BETA Related Diseases In force · Medium confidence | In force | Medium confidence | |
| US 9,163,082 | Methods for the Treatment of IL-1BETA Related Diseases In force · Low confidence | In force | Low confidence | |
| US 8,802,657 | Compounds Useful as Raf Kinase Inhibitors In force · High confidence | In force | High confidence | |
| US 9,556,177 | Substituted 1,3-Thiazoles as Synthetic Intermediates for Preparation of Raf Kinase Inhibitors In force · High confidence | In force | High confidence | |
| US 9,920,048 | Substituted Pyrimidines for Inhibiting Raf Kinase Activity In force · Medium confidence | In force | Medium confidence | |
| US 8,377,429 | Methods for Improvement of Beta Cell Function with ANTI-IL-1BETA Antibodies or Fragments Thereof In force · High confidence | In force | High confidence | |
| US 8,546,308 | Novel Triple Tag Sequences and Methods of Use Thereof In force · Low confidence | In force | Low confidence | |
| US 10,611,832 | Cardiovascular Related Uses of IL-1BETA Antibodies and Binding Fragments Thereof In force · Medium confidence | In force | Medium confidence |
Also on record, not counted in the 25: 15 patents in force now held by others · 43 lapsed for an unpaid fee · 138 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
2 abandoned · 15 no status recorded